Welcome to our dedicated page for DAMORA THERAPEUT news (Ticker: DMRA), a resource for investors and traders seeking the latest updates and insights on DAMORA THERAPEUT stock.
Damora Therapeutics, Inc. reports news around its biotechnology pipeline for mutCALR-driven blood disorders, financial results, and corporate development following the completed acquisition that added DMR-001, DMR-002, and DMR-003. Company updates also describe governance changes, board and executive appointments, and equity compensation actions under Nasdaq inducement-grant rules.
Recurring Damora news centers on hematologic disorders, myeloproliferative neoplasms, research and development progress, capital resources, and public-company governance matters tied to its Nasdaq-listed common stock.
Damora Therapeutics (NASDAQ: DMRA) reported second quarter 2026 results highlighted by initiation of the global Phase 1/1b CLARITY-101 trial of lead candidate DMR-001 in mutant calreticulin (mutCALR)-driven essential thrombocythemia and myelofibrosis, following health authority approvals.
The company also presented DMR-001 preclinical data at EHA 2026 showing up to 30-fold higher binding affinity, 26-fold greater inhibition of cellular proliferation in Type 2 mutCALR, and a five-fold longer half-life versus a reference antibody, supporting predicted once-monthly subcutaneous dosing. Biotech executive Dr. Andrew Cheng joined the board.
Cash and cash equivalents were $540.5 million as of June 30, 2026, which Damora Therapeutics expects to fund operations into the second half of 2029. Second quarter R&D expenses were $25.5 million and G&A $9.5 million, leading to a net loss of $31.2 million, compared with $3.4 million a year earlier. Upcoming milestones include first regulatory submissions for DMR-002 in the second half of 2026 and DMR-003 in 2027, and two clinical proof-of-concept datasets for DMR-001 beginning mid-2027.
Damora Therapeutics (NASDAQ: DMRA) has initiated the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational monoclonal antibody targeting mutant calreticulin (mutCALR), in adults with mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), following health authority approvals.
The open-label, multi-center dose-escalation and expansion study will evaluate safety, tolerability and preliminary efficacy, starting at a predicted-therapeutic dose of 100 mg once monthly by subcutaneous injection, using an adaptive Bayesian design for cohort enrichment. Eligible patients have documented CALR mutations and ET or MF resistant, refractory or intolerant to prior standard therapies, with expansion planned into earlier-line and combination settings.
DMR-001 is engineered to selectively block mutCALR–thrombopoietin receptor interactions while sparing wild-type calreticulin, with Fc-null and YTE half-life–extending modifications. According to Damora Therapeutics, preclinical data showed up to 30-fold higher mutCALR binding affinity and about five-fold longer half-life than a reference antibody, supporting once-monthly dosing. Initial clinical data are expected beginning mid-2027.
Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to six newly hired non-executive employees on August 1, 2026. The independent Compensation Committee approved these grants as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
The awards comprise stock options to purchase an aggregate of 451,000 ordinary shares, with a 10-year term and an exercise price of $28.99 per share. Each option vests 25% on the first anniversary of the employee’s start date and then in equal monthly installments over the following 36 months. The options are granted under the 2022 Damora Therapeutics Inducement Plan and are subject to the plan and related option award agreements.
Damora (NASDAQ: DMRA) completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. Each Delaware common share converted into one Cayman ordinary share, and each preferred share converted into the corresponding Cayman series. Nasdaq trading will continue under “DMRA” with a new CUSIP, G2646Y104, effective July 20, 2026. According to Damora, the move does not change its business, management, obligations, assets, or liabilities.
Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to nine newly hired, non-executive employees on July 1, 2026. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are non-qualified stock options for an aggregate 453,500 shares at a $26.01 exercise price.
The options have a 10-year term and vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months, under the 2022 Damora Therapeutics Inducement Plan and related award agreements.
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to six newly hired non-executive employees on June 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
The grants are non-qualified stock options for an aggregate 372,000 shares at a $24.88 exercise price, with a 10-year term and four-year vesting schedule.
Damora Therapeutics (NASDAQ: DMRA) reported first quarter 2026 results and pipeline progress. Cash and equivalents were $532.9 million as of March 31, 2026, expected to fund operations into 2029. Net loss was $27.8 million, with higher R&D and G&A expenses as programs advance.
Damora plans first regulatory submissions for DMR-001 in mid-2026, DMR-002 in second-half 2026, and DMR-003 in 2027, with two DMR-001 proof-of-concept datasets anticipated beginning mid-2027. DMR-001 preclinical data will be presented at the 2026 European Hematology Association Congress. The company also appointed Jennifer Jarrett as CEO and expanded its leadership team and board.
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards are non-qualified stock options for an aggregate of 57,500 shares, 10-year term, exercise price $25.66 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the 2022 Inducement Plan and individual option agreements.
Damora Therapeutics (NASDAQ: DMRA) announced inducement equity grants tied to recent hires and its new President and CEO, Jennifer Jarrett, on March 24 and March 30, 2026. The company granted non-qualified options totaling 74,000 shares to four non-executive hires at $23.05, with a 10-year term.
Ms. Jarrett received 500,000 RSUs and non-qualified options to purchase 1,500,000 shares at an exercise price of $25.50. Options vest 25% after one year, then monthly over 36 months; RSUs vest annually over four years. Grants were approved under Nasdaq Listing Rule 5635(c)(4) and subject to Damora's 2022 Inducement Plan and award agreements.
Damora Therapeutics (NASDAQ: DMRA) appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and added biotech leaders Cameron Turtle and Mike Landsittel to the Board. Peter Harwin was named Chairman. Management changes accompany a focus on advancing lead program DMR-001 and portfolio development.